NASCP BULLETIN
The National AIDs and STDs Control Programme

August 2020

NATIONAL DATA REPOSITORY (NDR)
Data used was downloaded from NDR on 06/08/2020

2,115,381
Number of individuals ever enrolled in care

243,263
Number of Patients who visited within the month

1,945
Registered Facilities on the NDR
Treatment facilities reported for July: 1130
SURGE facilities reported for July: 428

## SECOND 90: PATIENTS IN HIV CARE AND TREATMENT

Patients newly initiated on treatment (N = 24,373)

Age groups (Male / Female):
- 50+: 1,050 / (red)
- 45-49: 939 / 886
- 40-44: 1,424 / 1452
- 35-39: 1,510 / 2307
- 30-34: 1,754 / 2813
- 25-29: 1,886 / 3390
- 20-24: 1,126 / 1768
- 15-19: 225 / 371
- 10-14: 94 / 104
- 5-9: 87 / 95
- 1-4: 112 / 87
- <1: 13 / 31

Patients currently receiving treatment (N = 1,048,805)

Age groups (Male / Female):
- 50+: 78,791 / 95,302
- 45-49: 44,930 / 64,233
- 40-44: 55,024 / 108,447
- 35-39: 48,909 / 135,364
- 30-34: 39,212 / 132,000
- 25-29: 27,687 / 92,021
- 20-24: 15,673 / 41,878
- 15-19: 7,463 / 12,898
- 10-14: 9,115 / 9,286
- 5-9: 8,176 / 7,912
- 1-4: 3,654 / 3,689
- <1: 66 / 115

INDICATORS SUMMARY
Patient records uploaded as at the end of July 2020

| Indicators	Female (%)	Male (%)	Total
Treatment New	14,153 (58%)	10,220 (42%)	24,373
Treatment Current	710,105 (68%)	338,700 (32%)	1,048,805
LTFU	17,019 (68%)	8,033 (32%)	25,052
Death	53 (50%)	52 (50%)	105
Transferred Out	388 (69%)	171 (31%)	559

MONTHLY RETENTION ANALYSIS OF HIV PATIENTS RECEIVING ART FOR 2020

This graph presents monthly % retention of patients who were followed up from January 1st 2020, and those who entered the treatment program monthly (newly started on ART, transferred-in and re-initiated on ART) from January 2020 through July 2020

Monthly retention: January 97.0%, February 94.7%, March 92.4%, April 90.6%, May 89.1%, June 89.0%, July 89.0%

Indicators	January	February	March	April	May	June	July
Transferred Out	655 (0.1%)	727 (0.1%)	2,808 (0.4%)	335 (0.3%)	242 (0.4%)	242 (0.4%)	559 (0.4%)
Death	600 (0.1%)	708 (0.1%)	738 (0.2%)	51 (0.2%)	41 (0.1%)	42 (0.1%)	105 (0.1%)
LTFU	27,219 (2.8%)	22,833 (5.1%)	22,250 (7.0%)	23,105 (8.9%)	28,872 (10.4%)	27,436 (11.0%)	25,052 (10.0%)
Active (Retention rate)	919,587 (97.0%)	935,889 (94.7%)	959,681 (92.4%)	963,082 (90.6%)	962,586 (89.1%)	999,973 (89.0%)	1,048,805 (89.0%)

THIRD 90: VIRAL SUPPRESSION AND QUALITY OF CARE

Initial Viral Load (January 2020 cohort):
- Eligible: 98,736
- Tested: 46,485 (47%)
- Suppressed: 40,924 (88%)

Routine Viral Load (as at July 2020):
- Eligible: 707,276
- Tested: 548,789 (78%)
- Suppressed: 504,666 (92%)

Adults Regimen Analysis: TDF/3TC/DTG 87%, Other 1st Line 9%, 2nd Line 4%

Pediatrics (6-14 years) Regimen Analysis: TDF/3TC/DTG 41%, Other 1st Line 40%, 2nd Line 18%

KEY: *TDF - Tenofovir *3TC - Lamivudine *AZT - Zidovudine *NVP - Nevirapine *DTG - Dolutegravir * VL - Viral Load

The national prevalence of HIV is 1.3% (1.9 million people infected) and varies widely between 0.3% to 5.5% among states. Ten states with different saturation and unmet need account for about 70% of the burden. To reach epidemic control, Nigeria has scaled up evidence-based interventions tailored toward case finding, linkage to care with immediate ART initiation, and improved viral suppression.

Case fiding and Testing Yield in July 2020

Indicators	Akwa Ibom	Rivers	Lagos	Benue	FCT	Delta	Nasarawa	Enugu	Imo	Gombe
HTS_TST_POS	87,518	58,753	26,306	13,351	13,332	12,620	10,928	9,039	7,838	5,727
Treatment_New	85,294	58,227	25,173	18,847	13,193	12,473	10,943	8,970	7,895	5,705
Yield %	5.3%	3.4%	6.1%	7.5%	5.1%	3.3%	3.4%	6.8%	4.4%	4.0%

ART Initiation and Linkage to Treatment in July 2020

Indicators	Akwa Ibom	Rivers	Lagos	Benue	FCT	Delta	Nasarawa	Enugu	Imo	Gombe
HTS_TST_POS	87,518	58,753	26,306	13,351	13,332	12,620	10,928	9,039	7,838	5,727
Treatment_New	85,294	58,227	25,173	18,847	13,193	12,473	10,943	8,970	7,895	5,705
Linkage %	97%	99%	96%	141%	99%	99%	100%	99%	101%	100%

HTS_TST_POS: Number of individuals who received HIV Testing Services (HTS) and received their test results.

Treatment NEW: Number of adults and children newly enrolled on antiretroviral therapy (ART).

Yield: Percentage of Positive test results from testing program.

Linkage %: Percentage of HIV positive that linked for treatment initiation.

Trend of Treatment Current

State	TX_CURR Mar. 31, 2019 FY19Q2	TX_CURR Dec. 31, 2019 FY20Q1	TX_CURR Mar. 31, 2020 FY20Q2	TX_CURR Jun 30, 2020 FY20Q3	TX_CURR July 31, 2020 FY20Q3
Akwa Ibom	35,044	71,918	100,904	115,319	124,863
Benue	110,878	121,048	155,813	164,831	168,935
Delta	15,208	15,136	20,177	27,607	26,412
Enugu	18,110	19,674	22,692	25,269	26,612
FCT	38,185	42,089	43,973	49,652	52,744
Gombe	14,377	17,246	20,018	23,213	23,747
Imo	12,057	15,009	16,897	19,484	20,688
Lagos	57,935	46,046	59,411	63,925	70,191
Nasarawa	36,372	37,985	42,070	47,232	47,009
Rivers	26,041	46,705	61,540	77,820	83,361

*TX_CURR - Treatment Current

Data source: NDR

Nigeria Surge States
- Green States
- Red States
- State Boundary

The National Data Repository (NDR) is a Federal Ministry of Health project supported by PEPFAR.

NATIONAL STOCK STATUS

Data was sourced from the following data sets: May/June 2020 LMIS (NHLMIS) report from 36 States + the FCT, end of June Warehouse Reports from the Axial Warehouses as well as the GON and Partner Warehouses (FMS Oshodi, NCAPS-Abia, Calabar, Taraba, and DoD), central level stock report as at June 30, 2020.

ADULT ARVs – FIRST LINE

| Product	MOS IN-COUNTRY	MOS SHIPMENT
TDF/3TC/DTG (300/300/50mg) [TLD-30]	3.2	9.8
Dolutegravir DTG 50mg	5.5	19.4
TDF/3TC/EFV (300/300/600 mg)	33.9	
Efavirenz EFV 600 mg	14.5	
ABC/3TC (600/300mg)	6.7	14.1

■ MOS IN-COUNTRY   ■ MOS SHIPMENT

ADULT ARVs – SECOND LINE

Product	MOS In-country	MOS Shipment
Lopinavir | Ritonavir (LPV | r) 200/50mg	8.0	10.1
Atazanavir | Ritonavir (ATV | r) 300/100mg	2.6	13.6
Zidovudine AZT 300mg	3.6	0.5
TDF/3TC (300/300 mg)	6.5	17.0
AZT/3TC (300/150 mg)	9.0	7.2

■ MOS In-country   ■ MOS Shipment

PAEDIATRIC ARVS - FIRST LINE

Product	MOS In-country	MOS Shipment
Lopinavir | Ritonavir (LPV/r) 40/10mg	18.8	18.4
AZT/3TC/NVP (60/30/50mg)	29.5	0.0
AZT/3TC (60/30mg)	26.1	12.2
ABC/3TC (120/60mg)	4.5	11.6
Abacavir ABC (60mg)	19.4	0.0

■ MOS In-country   ■ MOS Shipment

PAEDIATRIC ARVS - SECOND LINE AND PMTC

Product	MOS In-country	MOS Shipment
Zidovudine AZT 50mg/5mL	6.4	6.5
Nevirapine NVP 50mg/5mL	9.2	4.4
Lopinavir | Ritonavir (LPV/r) 100/25mg	9.1	16.4

■ MOS In-country   ■ MOS Shipment

OPPORTUNISTIC INFECTIONS DRUGS

Drug	MOS In-country	MOS Shipment
Isoniazid (INH) 300mg	5.1	9.8
Isoniazid (INH) 100mg	20.8	1.8
Fluconazole oral suspension 50mg/5ml	6.1	47.0
Fluconazole 100mg	7.8	6.1
Co-trimoxazole 960mg	10.9	7.8
Co-trimoxazole 120mg	23.6	0.1

■ MOS In-country　■ MOS Shipment

RAPID TEST KITS

Test Kit	MOS In-country	MOS Shipment
Stat-Pak	12.1	8.6
Unigold	6.5	4.1
Determine	9.0	4.0

■ MOS In-country　■ MOS Shipment

TLD TRANSITION

Legend: AZT/3TC/NVP (300/150/200 mg) · TDF/3TC/EFV (300/300/600 mg) · TDF/3TC/DTG (300/300/50mg) [TLD-90]

PAEDIATRIC ART REGIMEN OPTIMIZATION

Legend: ABC/3TC (120/60mg) · AZT/3TC/NVP (60/30/50mg) · Lopinavir/Ritonavir LPV/r 100/25mg · Lopinavir/Ritonavir LPV/r 40/10mg

Data used was downloaded from LIMS (Laboratory Information Management System)

**473,072**
Samples sent for Testing

409,681
Valid samples tested

392,144
Samples dispatched

376
Samples rejected

EID CASCADE FOR JANUARY - JUNE 2020

22,039
Samples sent for testing

22,256
Total samples tested

19,072
Samples dispatched

47
Samples rejected

Legend:
- Sample received
- Valid sample tested
- Sample Dispatched
- Sample rejected

Y-axis: Number of Patients in thousands (0, 25, 50, 75)
X-axis: Months — January, February, March

Fig1: Multiple Bar chart showing Viral Load and EID Cascade

There is a signifcant gap between samples received for viral load and samples tested and this is largely due to machine downtime and sample backlog in a few high volume sites.

The range of turn around time for the Viral load is between 3 - 28 days while EID has a turn around time of 10 - 30 days.

VIRAL LOAD TABLE FOR THE MULTI BAR CHART

	January	February	March	April	May	June
Sample received	79,742	78,958	102,348	52,594	51,904	81,547
Sample Tested	60,519	72,265	77,624	60,285	47,281	54,751
Valid Sample tested	58,526	70,451	74,638	57,925	45,936	53,818
Sample despatched	48,793	69,072	74,279	60,349	45,401	49,839
Sample rejected	61	70	66	68	45	42

EID TABLE FOR THE MULTI BAR CHART

	January	February	March	April	May	June
Sample received	3,842	3,934	3,358	2,454	3,267	3,897
Sample Tested	4,325	3,570	3,904	2,201	3,392	3,736
Total Sample tested	4,383	3,641	3,992	2,318	3,484	3,804
Sample Rejected	14	9	10	7	3	4

PROGRAMME UPDATE

PSM SITUATION ROOM

The COVID-19 pandemic brought many uncertainties and the potential impact on HIV services was of particular concern. In order to avoid a disruption in ARV drug supply, a Situation Room was set up by NASCP to provide a platform for identifying and responding to emerging issues. The PSM situation room was activated on the 27th March 2020 and had representatives from NACA, NPSCMP, USAID, CDC, DOD, GHSC-PSM, CHAI, FHI360/GF, WHO, UNICEF, UNAIDS, LSMOH and AHF. Meetings are held virtually; Initially twice a week but now once weekly. The main goal of the PSM Situation Room is to constantly review the impact of global supply chain challenges on the national programme, share information, and provide guidance on measures to ensure supplies of commodities and other HIV services are sustained.

Specifcally, the Situation Room

• Provides regular updates to national and state level stakeholders on HIV PSM issues
• Closely monitors in-country stock situation and shipment status of commodities;
• Assesses the impact of border closure and restrictions on the supply chain;
• Determines how supply will be impacted and the key risks;
• Advises on demand planning based on stock situation; and
• Provides guidance in the event of supplies constraints to avoid service interruption.
•

Integrated Biological and Behavioral Surveillance Survey (IBBSS) 2020

The 2020 Nigeria IBBSS is designed to build on the lessons learned from the previous IBBSS, the 2012 NARHS Plus, the ANC Surveillance, and The Nigeria AIDS indicator Impact Survey. The proposed IBBSS will facilitate the measurement of behavioral risk factors and HIV status among selected key population in Nigeria. It aims to complement the knowledge gained so that viable education, prevention, and treatment programmes can be designed and implemented. It will further provide valuable information for stakeholders in the description and understanding of HIV dynamics and the effects of interventions. The outcome of this survey will provide opportunities for appropriate follow-up for clinical and social support services (counselling and testing, STI services, and "prevention with positives" support) including referrals.

A probability-based sampling method using multistage sampling technique will be used for sampling all the KP groups by typology. A total sample size of 18,324 will be drawn from twelve states: Abia, Anambra, Benue, Nasarawa, Akwa Ibom, Rivers, Taraba, Gombe, Lagos, Oyo, Kaduna and Kano.

Protocol development	IRB Approvals	Field work	Data analsysis and reporting	Dissemination of findings